Aprea discloses second clinical hold in a week, this time for lymphoma study
Barely a week after Aprea got hit with a clinical hold on a slate of myeloid malignancy trials, the biotech revealed its lymphoid malignancy program is also being halted.
In contrast to the previous disclosure, where the company didn’t specify a reason for the partial hold, Aprea said the FDA had concerns about its lymphoid malignancy study after reviewing safety and efficacy data from the Phase III MDS clinical trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.